据 wsj Mar 2009 报导. Biotechnology companies are gearing up for battle on Capitol Hill after Rep.Henry Waxman,the powerful California Democdat,introduced a bill that would clear a regulatory path for generic drug makers to produce copies of biologic medicines.
Companies such as Amgen Inc. and Genentech Inc.have fought off such efforts in the past.Biologics are generally proteins manufactured in living cells,and they are far more complex than traditional drugs that can be cooked up by mixing chemicals in well-defined steps.
spending on biologics is expected to exceed $100 billion by 2011,said representatives of the generic drug industry.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment